Skip to main content

Table 2 Comparison of upregulation incidences and detection accuracies of SFs and CEA in GC and CRC

From: Comparative expression patterns and diagnostic efficacies of SR splicing factors and HNRNPA1 in gastric and colorectal cancer

  Protein mRNA
  Stomach Colon and rectum GC vs. CRC, % difference (p b) Stomach Colon and rectum GC vs. CRC, % difference (p b)
UIa in paired samples; upregulated pair, n/total pair, n (%)  
  HNRNPA1 or HNRNPA1 31/60 (52) 106/121 (88) 36 (< 0.001) 20/45 (44) 55/96 (57) 13 (0.214)
  SRSF1 or SRSF1 13/60 (22) 38/121 (31) 10 (0.232) 17/45 (38) 37/96 (39) 1 (0.921)
  SRSF3 or SRSF3 20/60 (33) 89/121 (74) 40 (< 0.001) 20/45 (44) 46/96 (48) 3 (0.838)
  SRSF5 or SRSF5 15/60 (25) 48/121 (40) 15 (0.074) 16/45 (36) 20/96 (21) −15 (0.097)
  SRSF6 or SRSF6 17/60 (28) 63/121 (52) 24 (0.004) 16/45 (36) 46/96 (48) 12 (0.232)
  SRSF7 or SRSF7 25/60 (42) 69/121 (57) 15 (0.115) 18/45 (40) 45/96 (47) 7 (0.559)
  CEA 32/60 (53) 111/121 (92) 38 (< 0.001)
Detection accuracy, AUC       
 Allc (Sensitivity%/Specificity%) n = 147 n = 258   n = 111 n = 202  
 low-stage ACd n = 127 n = 197   n = 95 n = 153  
 high-stage ACd n = 103 n = 193   n = 78 n = 152  
  HNRNPA1 or HNRNPA1 0.74 (72/71) 0.90e (85/86) 17 (< 0.001) 0.58e,f (69/50) 0.69e,f (54/78) 11 (0.117)
  0.71 0.93 23 (< 0.001) 0.54e 0.71e,f 17 (0.030)
  0.77 0.89e 11 (0.141) 0.64e 0.64e,f 0 (1.000)
  SRSF1 or SRSF1 0.58e,f (95/23) 0.62e,f (42/82) 4 (0.487) 0.55e,f (49/65) 0.61e,f (88/35) 6 (0.399)
  0.56e 0.66e,f 10 (0.147) 0.53e 0.62e,f 9 (0.252)
  0.66e 0.58e,f −8 (0.314) 0.63e 0.58e,f −6 (0.552)
  SRSF3 or SRSF3 0.53e,f (53/57) 0.84e,f (81/78) 32 (<0.001) 0.59e,f (71/52) 0.65e,f (75/51) 7 (0.322)
  0.56e,f 0.84e,f 28 (< 0.001) 0.54e 0.68e,f 14 (0.069)
  0.55e,f 0.84e 29 (< 0.001) 0.60e 0.62e,f 16 (0.866)
  SRSF5 or SRSF5 0.51e,f (60/51) 0.62e,f (35/89) 11 (0.062) 0.52e,f (91/23) 0.52e,f (78/38) 0 (0.953)
  0.53e,f 0.65e,f 12 (0.101) 0.54e 0.51e,f −3 (0.718)
  0.62e 0.58e,f −3 (0.701) 0.53e,f 0.54e,f 1 (0.914)
  SRSF6 or SRSF6 0.61e,f (38/89) 0.76e,f (51/96) 14 (0.006) 0.58e,f (56/62) 0.67e,f (60/68) 9 (0.192)
  0.60e 0.78e,f 18 (0.004) 0.53e,f 0.68e,f 15 (0.062)
  0.56e,f 0.74e,f 18 (0.032) 0.61e 0.65e,f 4 (0.699)
  SRSF7 or SRSF7 0.63e (30/84) 0.74e,f (59/83) 11 (0.066) 0.54e,f (38/80) 0.65e,f (85/43) 11 (0.125)
  0.61e 0.75e,f 15 (0.036) 0.53e 0.66e,f 12 (0.126)
  0.71e 0.73e,f 3 (0.755) 0.70e 0.64e,f −6 (0.474)
  CEA 0.76 (57/89) 0.96f (92/94) 20 (< 0.001)
  0.77g 0.97 20 (< 0.001)
  0.90g 0.99f 9 (0.037)
  1. Abbreviations: AC adenocarcinoma, AUC area under the curve, CEA carcinoembryonic antigen, CRC colorectal cancer, GC gastric cancer, NM normal mucosa, UI upregulation incidence
  2. aUIs in cancer were acquired using paired samples from the same patient (cancer/NM >2-fold)
  3. b p value was acquired by chi-square test
  4. cAUCs were acquired for all types of cancer (including non-AC), regardless of TNM stage
  5. dAUCs were acquired for low-stage AC (TNM stage I/II AC) or for high-stage AC (TNM stage III/IV AC)
  6. e p < 0.05: compared with the respective AUC of CEA; p values for the paired AUC were acquired by the DeLong test
  7. f p < 0.05: compared with the respective AUC of HNRNPA1; p values for the paired AUC acquired by the DeLong test
  8. g p < 0.05: AUC of low-stage AC vs. AUC of high-stage AC; p values were acquired by independent receiver operating characteristic curve comparison test